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jurisdictions considering replicating the
MCC program. Of the remainder, some
costs related to protocol and assessment
tool development could potentially
be minimized by adapting materials
already developed for LAC MCC. The
annual cost per patient was $1100–$3100;
although the annual costs of similar pro-
grams vary widely,6–8 it is within the
range reported for these similar programs
and is also comparable with the cost of
a 1-month supply of a single-tablet cofor-
mulated antiretroviral therapy
medication.9
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The Effect of Switching
to Maraviroc +
Darunavir/Ritonavir
Dual Therapy in
Virologically
Suppressed Patients on
the Progression of Liver
Fibrosis: Findings From
a Randomized Study
In vitro and animal studies revealed
a potential protective role of CCR5 antag-
onists on reducing liver ﬁbrosis progres-
sion and protecting from developing
hepatocellular carcinoma.1 Hepatocytes
bear CXCR4 and CCR5, the 2 main
coreceptors for HIV entry into cells and
the blockade of coreceptors on hepatic
stellate cells, the major producers of
extracellular matrix in the liver, will slow
progression of liver ﬁbrosis, especially
due to HIV-envelope gp120–mediated ﬁ-
brogenesis modulation.2–5
The aim of present analysis was to
compare the evolution of liver ﬁbrosis
over time evaluated by surrogated bio-
marker assays in HIV-1–infected pa-
tients on a virologically successful
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antiretroviral therapy (stable HIV-1
RNA ,50 copies/mL), randomized to
switch to maraviroc + darunavir/r (MVC
+ DRV/r arm) qd or to continue the
current MVC-free 3-drug antiretroviral
therapy (ART) (3-drug ART arm).
Patients included in the study were
enrolled in the GUided Simpliﬁcation
with Tropism Assay (GUSTA) trial,
a multicenter, open-label, randomized
study (www.clinicaltrials.gov, number
NCT01367210), whose main results
have been published.6
Brieﬂy, GUSTA included patients
with HIV-1 RNA ,50 copies/mL for at
least 6 months, R5 tropism and CD4
counts .200 cells/mL for at least 3
months before enrollment; hepatitis B
virus–coinfected patients and those
with Child-Pugh B/C cirrhosis
were excluded.
We retrospectively evaluated
Fibrosis-4 (FIB-4) Index and aspartate
aminotransferase to Platelet Ratio Index
(APRI) scores, at baseline and after 12,
24, 48, and 96 weeks. The cutoff points
of serum marker tests of hepatic ﬁbrosis
were as follows: FIB-4 ,1.45 (F0-F1),
1.45–3.25 (indeterminate), and .3.25
(F3-F4); APRI ,0.5 (F0-F1), .1.5
(F2) and .2 (cirrhosis).
Differences between arms were
assessed by x2 and Student t test,
longitudinal within-group differences
by McNemar test. The FIB-4 Index
and APRI scores were used as continu-
ous variables; their predictors at baseline
and their change over time were inves-
tigated by linear regression.
We included 150 patients, 76
randomized to MVC + DRV/r arm and
74 to 3-drug ART arm. Baseline char-
acteristics were homogeneous between
arms except for relative younger age in
the MVC + DRV/r arm (median 47 yrs;
interquartile range [IQR] 40–52) than in
the 3-drug ART arm (50 yrs; IQR
44–57) (P = 0.08), more frequent Afri-
can ethnicity in the 3-drug ART arm
than in the MVC + DRV/r arm (8% vs.
1%) (P = 0.05), and FIB-4 median value
FIGURE 1. A, APRI score during follow-
up. B, FIB-4 during follow-up. No signifi-
cant difference between arms at each
time-point.
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higher in the MVC + DRV/r arm (1.15;
IQR 0.82–1.32) than in the 3-drug ART
arm (0.91; IQR 0.68–1.20) (P = 0.01).
APRI score was similar between arms:
0.23 (IQR 0.18–0.29) in the MVC +
DRV/r arm and 0.25 (IQR 0.20–0.33) in
the 3-drug ART arm (P = 0.12).
Overall, 89% (134/150) were men-
males and Caucasians; 41% (61/150) were
heterosexuals; 38% (57/150)
homosexuals/bisexuals; 7% (10/150) re-
ported history of injected drug use, 11
years of HIV (IQR 7–18), 10 years of
ART (IQR 6–15), CD4 at nadir 222 cells/
mmc (IQR 132–319) and at baseline 654
cells/mmc (IQR 506–905). Eighteen pa-
tients presented positive serology for
hepatitis C virus (HCV) and 8 had a detect-
able HCV RNA, 4 in each arms.
Sixteen (11%) presented diabetes
mellitus: 12% (9/76) in the MVC +
DRV/r arm and 9% (7/74) in the
3-drug ART arm (P = 0.04). At screen-
ing, nucleoside reverse transcriptase
inhibitors (NRTIs) were used in 95%
(143/150), nonnucleoside reverse tran-
scriptase inhibitors (NNRTIs) in 12% (18/
150), integrase strand transfer inhibitors
(INSTIs) in 18% (17/150), and protease
inhibitors (PIs) in 69% (103/150) of which
boosted PI in 63% (94/150) and DRV/r in
31% (47/150). No differences between
arms were observed in terms of dislypi-
demia (in 100/150, 66%), with total
cholesterol 203 mg/dL (IQR 173–230),
body mass index (23 kg/m2, IQR 22–26)
and glucose 89 mg/dL (IQR 82–100).
Median value of false positive rate at
geno2pheno was 43 (IQR 24–69), with
no differences between groups.
During observation in the 3-drug
ART arm (n = 74), NRTIs were used in
92%, NNRTIs in 16%, INSTIs in 15%,
PIs in 69%, boosted PI in 51%, and DRV/
r in 43%.
According to the cutoff points of
hepatic ﬁbrosis, FIB-4 in the MVC +
DRV/r arm was ,1.45 in 83% (63/76),
between 1.45 and 3.25 in 16% (12/76),
and .3.25 in 1% (1/76); in the 3-drug
ART arm, it was ,1.45 in 88% (65/74)
and between 1.45 and 3.25 in 12% (9/
74) (no one had FIB-4 .3.25).
Overall, APRI was ,0.5 in 91%
(137/150), and no one had.1.5 at baseline.
Based on the FIB-4 score, at 48
weeks progression to a higher level was
observed in 6% (4/63) in the MVC +
DRV/r arm and in 6% (4/65) in 3-drug
ART arm; in 3% (4/12) among those in
MVC + DRV/r arm and in 3% (3/9) in
3-drug ART arm, FIB-4 improved by at
least 1 stage, whereas the other patients
did not modify their FIB-4 stratum.
Based on the APRI score, at 48
weeks, signiﬁcant modiﬁcation of the
stratum was no observed.
In addition, no signiﬁcant differ-
ences between arms were observed in
platelet counts and alanine transaminase
changes at 48 weeks from baseline. We
observed a more profound decrease of
aspartate transaminase (AST) levels in the
MVC + DRV/r arm (mean change −4.19
IU/L, SD 7.2) vs. 3-drug ART arm (mean
change +0.58 IU/L, SD 9.9) (P = 0.007).
In a multivariable model adjusting
for risk factor for HIV acquisition and
duration of ART exposure, longer time
from HIV diagnosis (per 1 year increase
+0.031, 95% conﬁdence interval [CI]:
+0.007 to +0.055, P = 0.01), lower nadir
CD4+ cells count (+100 cells increase,
−0.060, 95% CI −0.107 to −0.014, P =
0.01), and HCV antibody positive status
(+0.321, 95% CI +0.000 to +0.642, P =
0.05) were associated with higher base-
line FIB-4 values. No factor indepen-
dently associated with baseline APRI
values was observed. During follow-up,
the APRI score decreased more promi-
nently in the MVC + DRV/r arm vs 3-
drug ART arm at week 12 (median
change −0.02; IQR −0.06 to +0.12 vs
−0.006; IQR −0.05 to +0.02; P = 0.28),
at week 48 (−0.04; IQR −0.09 to +0.02
vs +0.001; IQR −0.037 to +0.049; P =
0.01), and at week 96 (−0.03; IQR −0.06
to +0.01 vs +0.02; IQR −0.01 to +0.10;
P = 0.053) (Fig. 1A).
In a multivariable model, predic-
tors of APRI change at 48 weeks were
baseline APRI (−0.391; 95% CI −0.515
to −0.266; P , 0.001) and MVC +
DRV/r arm vs 3-drug ART arm (−0.040;
95% CI −0.006 to −0.074; P = 0.021).
FIB-4 also showed a trend toward
a more prominent reduction in the MVC +
DRV/r arm (−0.02; IQR −0.21 to +0.13) vs
3-drug ART arm (+0.02; IQR −0.23 to
+0.20) (P = 0.35) at week 48 (Fig. 1B).
Baseline FIB-4, but not study arm, predicted
FIB-4 modiﬁcations during follow-up.
In conclusion, we observed that
switch to MVC + DRV/r in HIV-
1–infected, but virologically suppressed
patients on 3-drug ART, was associated
with a slight but signiﬁcant improve-
ment of the APRI score over time as
compared with continuing 3-drug ART
without MVC. This MVC-containing
regimen did not signiﬁcantly inﬂuence
the longitudinal change of the FIB-4
score, possibly due to the presence of
age as a component of the score, which
was increasing over time in the study
patients, although a trend toward an
improvement was observed. Our obser-
vations are in agreement with experi-
ments showing a reduction of hepatic
stellate cells activation and ﬁbrosis pro-
gression and an improved survival in
a murine model of hepatocellular carci-
noma1 and in vitro observations on the
inhibitory effect of MVC on the accu-
mulation of ﬁbrillar collagens and extra-
cellular matrix proteins by human
hepatic stellate cells.7 Results from this
study are also in line with a previous
retrospective non-comparative analysis
on 71 HIV/HCV-coinfected patients
treated with MVC, showing a potential
beneﬁcial effect on liver ﬁbrosis mea-
sured by the APRI score.8 In a previous
prospective, non-controlled pilot study
on 24 HIV/HCV-coinfected patients
starting a MVC-based regimen, liver
ﬁbrosis was slightly but not signiﬁcantly
reduced, although observation was lim-
ited to 6 months.9 In addition, a recent
study suggests that a validated marker of
liver ﬁbrosis was reduced in HIV-
1–infected patients carrying the variant
allele CCR5 delta-32, associated with
reduced CCR5 expression, and in pa-
tients exposed to cenicriviroc, a CCR5/
CCR2 blockade agent.10
Our study adds to previous evi-
dence and has its strengths in the
randomized comparison, the study arm
treated with a homogeneous MVC-
containing regimen and the prospective
follow-up of the patients up to 96 weeks.
Its main limitation is the lack of infor-
mation on the liver histological pattern
modiﬁcation rather than indirect bio-
markers, as it remains unclear whether
their change truly reﬂects hepatic ﬁbro-
sis change. The lack of information on
patients’ alcohol consumption and the
absence of transient liver elastography
measurements also represent limitations
to this analysis.
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Further studies are warranted to
conﬁrm an antiﬁbrotic effect of CCR5
antagonist therapy.
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PD-1+ and TIGIT+ CD4
T Cells Are Associated
With Coronary Artery
Calcium Progression in
HIV-Infected Treated
Adults
To the Editors:
With the advent of antiretroviral
therapy (ART), AIDS-related morbidity
and mortality has declined allowing age-
related diseases, such as cardiovascular
disease (CVD), to emerge as new chal-
lenges for this population. With an effect
size of approximately 1.5–2.0, the
impact of HIV on CVD is independent
of traditional cardiovascular risk factors
and antiretroviral medications.1 Immune
activation of monocytes and macro-
phages has been implicated in the higher
CVD risk in individuals with chronic
HIV. Coronary artery calcium (CAC)
is an indicator of subclinical coro-
nary artery atherosclerosis predictive
of coronary events including the
onset of myocardial infarction and
coronary-related deaths.2 Two research
groups, including our own, have pub-
lished that activated CD16+
monocytes/macrophages predict greater
CAC progression among HIV-infected
persons over a 2-year period.3,4
HIV-associated immune dysfunc-
tion is also characterized by T-cell
dysfunction; their role in HIV-
associated atherosclerosis has been less
studied. T-cell exhaustion is character-
ized by an expansion of negative check-
point receptors (NCRs) including PD-1
(programmed cell death protein 1), TIM-
3 (T-cell immunoglobulin and mucin-
domain containing-3), and TIGIT (T-cell
immunoreceptor with Ig and ITIM do-
mains). During chronic infection or
cancer, T-cell exhaustion results in the
progressive loss of effector function,
upregulation of inhibitory receptors,
and failure to transition to a quiescent
state.5 We have recently reported that
the expansion of NCR on CD4+ T cells
is associated with comorbidities of cog-
nitive impairment and fat loss in HIV-
infected individuals on ART.6,7 In this
study, we sought to examine the impact
of NCR-expressing T cells on CVD. We
hypothesized that higher baseline PD-
1–expressing and/or TIGIT-expressing
CD4+ T cells will be associated with
progression of CAC after 2 years in
chronically HIV-infected individuals on
stable ART.
T-cell immunophenotyping was
performed on banked peripheral blood
mononuclear cells from HIV-infected
individuals enrolled in the Hawaii Aging
with HIV-Cardiovascular Disease
(HAHC-CVD) Cohort Study,8 a longi-
tudinal study of subclinical CVD risk in
individuals with chronic HIV age .40
years and on ART for $3 months. Data
on CVD risk factors, as well as meta-
bolic data from fasting blood, were
available and allowed calculation of the
Framingham Risk Score (FRS) using
the National Cholesterol Education Pro-
gram website (http://hp2010.nhlbihin.
net/atpiii/calculator.asp). As previously
reported,8 computer tomography (CT)
examinations for CAC were performed
locally in Honolulu, HI, using a dual-
source CT scanner (Siemens 64-slice
Somatom) with quantiﬁcation of CAC
centrally at the Los Angeles Biomedical
Research Institute (M Budoff).
Cryopreserved peripheral blood
mononuclear cell were thawed and
stained for viability and the frequency
of expression at baseline of TIGIT, PD-
1, and TIM-3 on CD4+ and CD8+ T cells
were assessed by ﬂow cytometry fol-
lowing previously published methods.9
Isotype controls or ﬂuorescence minus
one controls were used to facilitate
gating. Software-based compensation
was performed on FlowJo (Treestar).
The predictive impact of NCR-
expressing T cells and other immuno-
logic parameters on 2-year change in
CAC was assessed by logistic regres-
sion, dichotomizing the participants into
those who demonstrated progression of
CAC and those whose level showed no
progression. A multivariate logistic
regression model was constructed.
Because of the small sample size,
FRS was used as a composite marker
of traditional CVD-risk factors. We, as
well as others, have reported a corre-
lation between monocyte immune
activation and change in CAC. We
therefore further examined the rela-
tionship between NCR-expressing
T cells and monocyte subsets based
on CD16 expression (classical, inter-
mediate, and nonclassical monocytes),
hypothesizing that any impact of
NCR-expressing T cells on CAC
may be mediated through an increase
in monocyte immune activation. A
two-sided P-value (P) , 0.05 was
considered as statistically signiﬁcant.
Analyses were performed using SPSS
version 24 (IBM, Armonk, NY).
The data consisted of 43 HIV-
infected participants who were predom-
inantly male (88%) and Caucasian
C.S. has received grants (R01HL095135 and
U54MD007584) from the National Institutes
of Health. For the remaining authors have no
funding or conﬂicts of interest to disclose.
J Acquir Immune Defic Syndr  Volume 81, Number 1, May 1, 2019 Letters to the Editor
Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved. www.jaids.com | e21
